Avellino Selects New Chief Executive Officer
Molecular diagnostic and gene therapy developer Avellino has appointed Jim Mazzo as its new CEO and president.
Mazzo brings more than 38 years of experience, including 22 years as the head of Allergan’s North American and European eye care organizations. He previously served as AdvaMed’s board chairman and as vice chairman and trustee for Chapman University and the University of San Diego.
Avellino is focused on developing eye care products, but has also earned an Emergency Use Authorization from the FDA for a COVID-19 diagnostic test.